Jared Pitts

TL;DR: Remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and in mice infected with chimeric virus, supporting its further clinical testing for treatment of COVID-19.

TL;DR: Remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and supports its further clinical testing for treatment of COVID-19.

TL;DR: A drug discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp) as mentioned in this paper.

TL;DR: In this paper, the key enzymes involved in the Remdesivir metabolic pathway with multiple parallel approaches were profiled, including bioinformatic analysis of nucleoside/nucleotide metabolic enzyme mRNA expression using public human tissue and lung single-cell bulk mRNA sequence (RNA-seq) data sets, protein and mRNA quantification of enzymes in human lung tissue and primary lung cells, biochemical studies on the catalytic rate of key enzymes, effects of specific enzyme inhibitors on the GS-443902 formation, and the effects of these inhibitors on RDV antiviral activity against

TL;DR: Analysis of nearly 6 million publicly available variant isolate sequences confirmed that Nsp12, the RNA-dependent RNA polymerase target of RDV and GS-441524, is highly conserved across variants, with only 2 prevalent changes (P323L and G671S).